Maasstad Ziekenhuis Stichting
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department focuses on improving outcomes for patients with ischemic stroke and transient ischemic attack, evaluating new antithrombotic strategies and optimizing post‑stroke care.
- Stroke prevention therapies
- Antiplatelet and anticoagulant safety
- Quality of life after stroke
Research at Maasstad Ziekenhuis Stichting aims to reduce recurrent events while balancing bleeding risk, offering patients safer long‑term protection.
Digestive System Diseases
Studies target chronic inflammation of the pancreas, seeking better pain control and disease management for individuals with chronic pancreatitis.
- Analgesic optimization
- Impact on daily functioning
- Early intervention strategies
The goal is to enhance comfort and reduce reliance on high‑dose medications for affected patients.
Female Urogenital Diseases and Pregnancy Complications
Research explores fertility support, including hormonal and procedural adjuncts to improve live‑birth rates for couples facing unexplained subfertility.
- Luteal phase support efficacy
- Cost‑effectiveness of adjunct therapies
- Outcomes of mild ovarian stimulation
By refining treatment protocols, the site seeks to increase successful pregnancies with minimal intervention.
Male Urogenital Diseases
Clinical work evaluates treatment duration and quality of life for men with prostate cancer, focusing on androgen‑targeted therapies and rehabilitation.
- Shortened androgen receptor inhibitor use
- Metastatic castration‑sensitive prostate cancer outcomes
- Penile rehabilitation strategies
The investigations aim to maintain disease control while reducing side effects and preserving sexual health.
Neoplasms
A broad oncology program addresses blood cancers and solid tumors, testing novel immunotherapies and targeted agents for diseases such as diffuse large B‑cell lymphoma, multiple myeloma, and chronic lymphocytic leukemia.
- Immunotherapy consolidation after chemotherapy
- Fixed‑duration combination regimens
- Minimal residual disease monitoring
Efforts are directed toward extending remission periods and improving survival without increasing toxicity.
Virus Diseases
The site conducts studies on antiretroviral management for individuals living with human immunodeficiency virus (HIV), focusing on regimen simplification and sustained viral suppression.
- Switch to single‑tablet therapy
- Long‑term safety in older adults
- Maintenance of virologic control
Findings aim to enhance adherence and quality of life for patients on chronic HIV treatment.
Reproductive and Urinary Physiological Phenomena
Investigations address normal and pathological processes of the urinary and reproductive systems, including erectile function recovery and fertility enhancement.
- Sildenafil dosing strategies for erection quality
- Role of hormonal support in assisted reproduction
- Physiological outcomes after urological interventions
The department seeks to translate physiological insights into practical therapies that improve patient well‑being.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 203 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 199 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Maasstad Ziekenhuis Stichting
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of Rituximab and Cyclophosphamide Versus Rituximab Monotherapy in Patients with ANCA-Associated Vasculitis | Leids Universitair Medisch Centrum (LUMC) | Phase III | Recruiting | May 2019 | — |
IMP list
lock Showing 1 of 203 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2019-07-01 | 2025-12-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.